Skip to main
HOWL
HOWL logo

Werewolf Therapeutics (HOWL) Stock Forecast & Price Target

Werewolf Therapeutics (HOWL) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Werewolf Therapeutics Inc. is demonstrating substantial advancements in its biopharmaceutical offerings, particularly through its proprietary PREDATOR platform and promising candidates like WTX-124 and WTX-330, which have shown encouraging clinical activity and manageable safety profiles. The company has reported significant preclinical and clinical trial data that highlight the potential of its INDUKINE molecules to selectively activate in the tumor microenvironment while minimizing systemic toxicity, thereby extending efficacy and dosing flexibility. With the anticipated initiation of phase 1/2 studies for WTX-330 and a de-risked masking strategy supporting further development across various immune-mediated indications, Werewolf's innovations position it favorably within the oncology landscape and beyond.

Bears say

Werewolf Therapeutics Inc reported a significant net loss of $20.4 million, or $0.46 per share, for the fourth quarter of 2024, which marked an increase from the $12.0 million loss reported in the same quarter of the previous year. The firm faces substantial risks associated with its WTX-124 program, including potential clinical or regulatory setbacks that could hinder revenue growth and lead to greater financial instability. Additionally, concerns have been raised regarding the ability of WTX-124 to demonstrate unique safety, efficacy, and pharmacokinetic properties, which could result in commercial challenges in a competitive market for cancer therapeutics.

Werewolf Therapeutics (HOWL) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Werewolf Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Werewolf Therapeutics (HOWL) Forecast

Analysts have given Werewolf Therapeutics (HOWL) a Buy based on their latest research and market trends.

According to 8 analysts, Werewolf Therapeutics (HOWL) has a Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Werewolf Therapeutics (HOWL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.